New drug LYNC-101 enters first human trials for ulcerative colitis

NCT ID NCT07505030

Not yet recruiting Disease control Sponsor: LyncBio Therapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests the safety of an experimental drug called LYNC-101 in 50 healthy adults. The drug is given by IV infusion, either as a single dose or multiple doses every 3 weeks. The goal is to see if it is safe and how the body processes it, before testing it in people with ulcerative colitis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LYNC-101 (an experimental drug given by IV infusion)
What this could lead to: If successful, this could lead to a new treatment option for ulcerative colitis, helping control the disease and reduce symptoms.
What could go wrong: This is an early Phase 1 trial in only 50 healthy people, not patients. It primarily checks safety, not effectiveness. Many drugs fail in early testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UC - ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UC - ULCERATIVE COLITIS

Contacts and locations

Locations

CMAX Clinical Research Pty Ltd

Adelaide, South Australia, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.